These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32552370)

  • 1. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Mod Rheumatol; 2021 Jan; 31(1):261-269. PubMed ID: 32552370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Ann Rheum Dis; 2021 Nov; 80(11):1483-1490. PubMed ID: 34158371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    Honda M; Horiuchi H; Torii T; Nakajima A; Iijima T; Murano H; Yamanaka H; Ito S
    BMC Pediatr; 2021 Dec; 21(1):581. PubMed ID: 34922491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
    Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
    Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
    Hakoda M; Kasagi F
    Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia.
    Hashimoto H; Takeuchi M; Kawakami K
    Clin Rheumatol; 2023 Nov; 42(11):3075-3082. PubMed ID: 37486577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
    BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
    Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
    Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
    Levy GD; Rashid N; Niu F; Cheetham TC
    J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
    Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
    Terkeltaub R
    Drugs; 2023 Nov; 83(16):1501-1521. PubMed ID: 37819612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.
    Akari S; Nakamura T; Furusawa K; Miyazaki Y; Kario K
    J Clin Hypertens (Greenwich); 2022 Aug; 24(8):1068-1075. PubMed ID: 35818841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.